A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities
NCT ID: NCT02915224
Last Updated: 2022-06-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2016-11-23
2021-06-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
NCT01905943
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
NCT02242942
Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina
NCT03059251
Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia
NCT02042911
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01868893
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Obinutuzumab
Participants will receive obinutuzumab as per Summary of Product Characteristics in daily practice along with chlorambucil for 24 months.
Chlorambucil
Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
Obinutuzumab
Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chlorambucil
Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
Obinutuzumab
Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University General Hospital of Alexandroupolis; Haemotology
Alexandroup, , Greece
Laiko General Hospital of Athens; A Propedeutical Clinic of Internal Medicine
Athens, , Greece
Laiko General Hospital; Hematology Clinic
Athens, , Greece
General Hospital G. Gennimatas; Hematology Dept.
Athens, , Greece
Attiko Hospital; Haematology Clinic
Athens, , Greece
Periph. University General Hospital of Heraklion; Hematology
Heraklion, , Greece
University Hospital of Larissa; Hematology Dept.
Larissa, , Greece
University General Hospital of Patra; Internal Medicine Clinic - Hematology Department
Pátrai, , Greece
Metaxa Hospital; Hematology Clinic
Piraeus, , Greece
AXEPA Pathology Section; A Pathology Clinic
Thessaloniki, , Greece
General Hospital G. Papanikolaou; Hematology, BMT Unit
Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML30133
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.